ArticleHematology, transfusion and cell therapy

Peripheral lymphocyte subsets as predicting factors for molecular recurrence after imatinib discontinuation in a phase 2 imatinib discontinuation trial in patients with chronic myeloid leukemia.

Arthur Gomes Oliveira Braga et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.